ArticleDiscover oncology2025
Construction of lactylation-related prognostic signature for glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Single-Cell and RNA Sequencing to Predict Glioma Prognosis Through Lactylation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma was a kind of malignant tumor associated with high mortality and recurrence. Therefore, it was urgent to establish effective prognostic models to guide clinical treatment in glioma. Protein lactylation was discovered in various malignant tumor, but only a few studies on glioma focused on protein lactylation.
methodsThe expression levels of lactylation-related genes were identified from the TCGA database. A lactylation-related prognostic signature was established using various combinations of 10 different excellent machine learning methods. The prognostic value of the signature was assessed and further validated in the CGGA cohorts. Patients were divided into two groups according to the risk score (RS). Independent prognostic value assessment, pathways enrichment analysis and protein-protein interaction analysis were conducted. Finally, we verified the functions of C19orf53 through vitro experiments.
resultsA robust lactylation-related prognostic signature of low-grade glioma (LGG) was established, which was consisted of 14 genes. Patients with higher RS had poorer clinical outcomes in all the cohorts. More immune-related and pro-cancer pathways were enriched in high-RS subgroup. Moreover, the 14 lactylation-related prognostic genes had close interaction relationships, and 11 of them had independent prognostic value. Vitro experiments proved that shRNA-mediated C19orf53 down-regulation impeded the migration and proliferation of LGG cells.
conclusionsThe lactylation-related prognostic signature exhibited robust predictive efficiency in LGG, providing a new perspective for the prognosis evaluation of LGG patients and the subsequent studies on therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.